Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Predicting Disease Activity and Improvement in CLE

J Am Acad Dermatol; ePub 2018 Jul 2; Ker, Teske, et al

Baseline Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) >9, minority race, and shorter disease duration predict cutaneous lupus erythematosus (CLE) disease activity improvement. This according to a recent study in which researchers characterized and compared the disease course of CLE patients using CLASI. 83 patients with CLASI scores collected from ≥3 study visits within 2 years had disease activity and damage trends calculated by average change scores (ACS). Trends were classified as “improved” (ACS ≤-3), “worsened” (ACS ≥+3), or “stable” (-3< ACS<+3). Linear regression models compared CLASI trends between groups. They found:

  • 72.73% with initial CLASI activity (CLASI-A) >9 (n=33) had improved disease activity vs 14.00% with initial CLASI-A ≤9 (n=50).
  • Linear regression analyses showed significant improvement in CLASI-A scores in patients with baseline CLASI-A >9, baseline CLASI damage (CLASI-D) ≥10, minority races, and CLE disease duration ≤1 year.
  • 35.71% with baseline CLASI-D ≥10 (n=28) had improving disease damage vs 5.26% with initial CLASI-D=5-9 (n=19) and 0% with initial CLASI-D <5 (n=36).

Citation:

Ker KJ, Teske NM, Feng R, Chong BF, Werth VP. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. [Published online ahead of print July 2, 2018]. J Am Acad Dermatol. doi:10.1016/j.jaad.2018.06.040.

This Week's Must Reads

ALT-70 Gets High Marks for Diagnosing Cellulitis, J Am Acad Dermatol; ePub 2018 Jul 9; Li, et al

MMS/MART-1 Immunostaining for Atypical Melanocytes, J Am Acad Dermatol; ePub 2018 Jul 9; Etzkorn, et al

Economic Analysis of Noninvasive Pathologic Assay, JAMA Dermatology; ePub 2018 Jul 11; Hornberger, et al

Use of Advanced Practice Professionals on the Rise, JAMA Dermatology; ePub 2018 Jul 11; Zhang, et al

Folate and Risk of Cutaneous Melanoma in Women, Cancer Epidemiol; 2018 Aug; Dhana, Ten, Li, et al

Must Reads in Mixed Topics

Predicting Disease Activity and Improvement in CLE, J Am Acad Dermatol; ePub 2018 Jul 2; Ker, Teske, et al

FDA Approves Qbrexza for Excessive Armpit Sweating, Dermira Inc. news release; 2018 Jun 29

Pretransplant History, Melanoma Outcomes Examined, Melanoma Res; ePub 2018 Jun 26; Puza, Barbas, et al

Psoriasis, Nonalcoholic Fatty Liver Disease Linked, J Clin Asthet Dermatol; 2018 Jun 1; Awosika, et al

Association Found Between HS and Crohn’s Disease, JAMA Dermatology; ePub 2018 May 23; Garg, et al